Actavis eyes $100 million after OxyContin settlement

29-04-2013

Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.

To read the rest of this story, register here for free content, or subscribe for access to archive.

For access to the complete website, archive, and to receive print publications, choose 'SUBSCRIBER'. For access to the latest news on the website and weekly email news alerts choose the 'FREE' registration. 

lsiprjuly2013thumbnail.jpg

actavis, oxycontin, purdue pharma, Fitzpatrick, Cella, Harper & Scinto